PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Seiler, L.K.* ; Phung, N.L.* ; Nikolin, C.* ; Immenschuh, S.* ; Erck, C.* ; Kaufeld, J.* ; Haller, H.* ; Falk, C.S.* ; Jonczyk, R.* ; Lindner, P.* ; Thoms, S.* ; Siegl, J.* ; Mayer, G.* ; Feederle, R. ; Blume, C.A.*

An antibody-aptamer-hybrid lateral flow assay for detection of CXCL9 in antibody-mediated rejection after kidney transplantation.

Diagnostics 12:308 (2022)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Chronic antibody-mediated rejection (AMR) is a key limiting factor for the clinical outcome of a kidney transplantation (Ktx), where early diagnosis and therapeutic intervention is needed. This study describes the identification of the biomarker CXC-motif chemokine ligand (CXCL) 9 as an indicator for AMR and presents a new aptamer-antibody-hybrid lateral flow assay (hybrid-LFA) for detection in urine. Biomarker evaluation included two independent cohorts of kidney transplant recipients (KTRs) from a protocol biopsy program and used subgroup comparisons according to BANFF-classifications. Plasma, urine and biopsy lysate samples were analyzed with a Luminex-based multiplex assay. The CXCL9-specific hybrid-LFA was developed based upon a specific rat antibody immobilized on a nitrocellulose-membrane and the coupling of a CXCL9-binding aptamer to gold nanoparticles. LFA performance was assessed according to receiver operating characteristic (ROC) analysis. Among 15 high-scored biomarkers according to a neural network analysis, significantly higher levels of CXCL9 were found in plasma and urine and biopsy lysates of KTRs with biopsyproven AMR. The newly developed hybrid-LFA reached a sensitivity and specificity of 71% and an AUC of 0.79 for CXCL9. This point-of-care-test (POCT) improves early diagnosis-making in AMR after Ktx, especially in KTRs with undetermined status of donor-specific HLA-antibodies.
Impact Factor
Scopus SNIP
Altmetric
3.992
1.100
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Antibody ; Antibody-mediated Rejection (amr) ; Aptamer ; Aptamer-antibody-hybrid Lateral Flow Assay (hybrid-lfa) ; Biomarkers ; Cxcl9 (mig) ; Neural Net Analysis; Donor-specific Antibody; Non-hla Antibodies; Urinary Cxcl9; Ifn-gamma; Activation; Chemokines; Classification; Expression; Challenges; Induction
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 2075-4418
e-ISSN 2075-4418
Zeitschrift Diagnostics
Quellenangaben Band: 12, Heft: 2, Seiten: , Artikelnummer: 308 Supplement: ,
Verlag MDPI
Verlagsort St Alban-anlage 66, Ch-4052 Basel, Switzerland
Begutachtungsstatus Peer reviewed
Institut(e) CF Monoclonal Antibodies (CF-MAB)
POF Topic(s) 30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-502210-001
A-631900-001
Förderungen Central Innovation Program for Small and Medium Entrepreneurs of the Federal Ministry for Economic Affairs and Energy Germany
German Center for Infection Research
Deutsche Forschungsgemeinschaft
DOI 10.3390/diagnostics12020308
WOS ID WOS:000763949100001
Scopus ID 85124327642
PubMed ID 35204399
Erfassungsdatum 2022-06-24
[➜Korrektur melden]